Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Sera Prognostics's Total Liabilities for the quarter that ended in Jun. 2026 was $27.36 Mil. Sera Prognostics's Total Assets for the quarter that ended in Jun. 2026 was $86.74 Mil.
Therefore, Sera Prognostics's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.32.
Sera Prognostics (NAS:SERA) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Sera Prognostics Liabilities-to-Assets Related Terms
Sera Prognostics Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Sera Prognostics's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SERA vs ZOMDF, OM, LNSR: Liabilities-to-Assets Comparison
For the Medical Devices subindustry, Sera Prognostics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics Liabilities-to-Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's Liabilities-to-Assets falls into.
Sera Prognostics Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Sera Prognostics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a Liabilities-to-Assets of 0.32 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Sera Prognostics and its competitors.
Is Sera Prognostics' Liabilities-to-Assets too high?
Sera Prognostics' current Liabilities-to-Assets is 0.32. Overall, Sera Prognostics has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' Liabilities-to-Assets compare to ZOMDF and OM?
Sera Prognostics' Liabilities-to-Assets of 0.32 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Sera Prognostics and its competitors. Sera Prognostics's current Liabilities-to-Assets is 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.81, compared to a current price of $2.04 — trading 12.7% above its estimated fair value. The current Liabilities-to-Assets is 0.32. Sera Prognostics' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Sera Prognostics (SERA), the current Liabilities-to-Assets is 0.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued.
The current stock price of $2.04 is trading 12.7% above its estimated GF Value™ of $1.81.
GuruFocus considers Sera Prognostics to be Modestly Overvalued.
Key valuation signals for SERA:
Liabilities-to-Assets: 0.32
GF Value™: $1.81 vs. price of $2.04 (12.7% above fair value)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
71GF Score
Get the complete analysis for SERA
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
